Medications for Stress Incontinence

Introduction to Stress Incontinence Management

• The American College of Physicians provides a strong recommendation against systemic pharmacologic treatment for stress urinary incontinence based on low-quality evidence showing lack of efficacy 1

Non-Pharmacologic Therapy

• Pelvic floor muscle training (PFMT) is the only recommended treatment for stress incontinence, with strong evidence demonstrating increased continence rates and improved quality of life 1, 2
• PFMT is more cost-effective than medications, has no adverse effects, and should always be prioritized 1

Pharmacologic Therapy Limitations

• Standard pharmacologic therapies used for urgency incontinence (antimuscarinics) have not been shown effective for stress incontinence 1
• Duloxetine showed limited efficacy with a number needed to benefit (NNTB) of 13, and did not achieve statistically significant improvement compared to placebo 2
• Duloxetine failed to improve quality of life in women with severe stress incontinence 2

Special Considerations

• For postmenopausal women, vaginal estrogen tablets or ovules may be considered as they demonstrated improvement with an NNTB of 5 2
• Transdermal estrogen patches should be avoided as they worsened urinary incontinence 1

Treatment of Mixed Incontinence

• Combined PFMT with bladder training is first-line treatment for patients with both stress and urgency components 1, 2
• If pharmacotherapy becomes necessary, it should target only the urgency component 3

Adjunctive Interventions

• For obese women with stress incontinence, weight loss and exercise are strongly recommended with moderate-quality evidence showing symptom reduction 1, 2
• The American College of Physicians recommends against prescribing antimuscarinics (oxybutynin, tolterodine, solifenacin, etc.) for stress incontinence, as they are only effective for urgency incontinence 1, 2